Skip to main content
MedPathMedPath Home
Clinical Trials/NCT03344822
NCT03344822
Unknown
Phase 2

Place of 68Ga-PSMA-11 PET-CT in the Therapeutic Decision at the End of the Initial Staging for High Risk Prostate Cancer Patients in Comparaison of 18F-Choline PET-CT

Central Hospital, Nancy, France1 site in 1 country33 target enrollmentJanuary 2, 2018
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsProstate Cancer

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Prostate Cancer
Sponsor
Central Hospital, Nancy, France
Enrollment
33
Locations
1
Primary Endpoint
percentage of modification of management intent
Last Updated
8 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

Several studies have shown a great potential of 68Ga-PSMA PET in high risk prostate cancers patients and a high detection rate than 18F-Choline PET.

The primary aim of this study is to evaluate the difference of management intent, after the inital staging of high risk prostate cancer patients, with 68Ga-PSMA-11 PET-CT results in comparison of 18F-Choline PET-CT results.

Registry
clinicaltrials.gov
Start Date
January 2, 2018
End Date
December 31, 2019
Last Updated
8 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Male

Investigators

Sponsor
Central Hospital, Nancy, France
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •high risk prostate cancer patients with initial tests : CT, bone scintigraphy and 18F-Choline

Exclusion Criteria

  • •contraindication of 68Ga-PSMA PET-CT

Outcomes

Primary Outcomes

percentage of modification of management intent

Time Frame: 1 month

modification of management intent after 68Ga-PSMA PET-CT and 18F-Choline PET-CT

Study Sites (1)

Loading locations...

Similar Trials

Active, not recruiting
Phase 2
An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer
NCT04777071University of Washington141
Completed
Phase 2
Gallium-68 PSMA-11 PET in Patients With Biochemical RecurrenceProstate CancerProstate AdenocarcinomaProstate Cancer MetastaticProstate Cancer Recurrent
NCT03396874University of Michigan1,435
Unknown
Not Applicable
Ga-68 PSMA-11 PET/CT in Patients With Biochemical Recurrence of Prostate Cancer: Digital PET/CT Versus Analog PET/CTProstate Cancer
NCT04846894Jin-Sook Ryu43
Completed
Phase 3
68Ga-PSMA-11 PET in Patients With Prostate CancerProstate CancerProstate Adenocarcinoma
NCT05197257University of Colorado, Denver39
Completed
Phase 2
Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy PatientsProstate Cancer
NCT02919111University of California, San Francisco299